Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Biochemical Recurrence in Prostate Cancer and Temporal Association to Bone Metastasis.

Mahdy A, Patil R, Parajuli S.

Am J Case Rep. 2019 Oct 16;20:1521-1525. doi: 10.12659/AJCR.918569.

2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
4.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
5.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
6.

Natural history of progression after PSA elevation following radical prostatectomy.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC.

JAMA. 1999 May 5;281(17):1591-7.

PMID:
10235151
7.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
8.

Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.

Kumar A, Samavedi S, Mouraviev V, Bates AS, Coelho RF, Rocco B, Patel VR.

J Robot Surg. 2017 Mar;11(1):37-45. doi: 10.1007/s11701-016-0606-8. Epub 2016 May 31.

PMID:
27245233
9.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

10.

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N.

Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. Review.

11.

[PSA and follow-up after treatment of prostate cancer].

Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.

Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Review. French.

PMID:
18472065
13.

Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy.

Donin NM, Laze J, Zhou M, Ren Q, Lepor H.

Urology. 2013 Jul;82(1):148-52. doi: 10.1016/j.urology.2013.03.054. Epub 2013 May 22.

PMID:
23706588
14.
15.

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):149-55. doi: 10.1007/s00259-012-2272-z. Epub 2012 Nov 14.

PMID:
23151910
16.

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

Pound CR, Partin AW, Epstein JI, Walsh PC.

Urol Clin North Am. 1997 May;24(2):395-406.

PMID:
9126237
17.

Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.

Do T, Parker RG, Do C, Tran L, Do L, Dolkar D.

Cancer J Sci Am. 1998 Sep-Oct;4(5):324-30.

PMID:
9815297
18.
19.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.

BJU Int. 2014 Dec;114(6b):E120-E129. doi: 10.1111/bju.12771. Epub 2014 Aug 13.

20.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559

Supplemental Content

Support Center